Salute e Benessere

Investors Eye Next-Gen 3D AI-Imaging Technologies in Growing $9 Billion Market

Click here to view the custom infographic of the Izotropic Corporation editorial. Clickhereto view the custom infographic of the Izotropic Corporationeditorial. AI and 3D Imaging: The New Frontiers of Detection The convergence of AI and three-dimensional (3D) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the...
PR Newswire
21/10/2025

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of…

Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 Genmab A/S(Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) ofMerus N.V.(Nasdaq: MRUS) (“Merus”)for $97.00 per Common Share in cash(the “Offer Consideration”) , less any...
Nasdaq GlobeNewswire
21/10/2025

Mesh Suture, Inc. Secures Key Regulatory Approvals, Accelerating Global Access…

The MDR certification, under the EU's latest regulatory framework, ensures that DURAMESH™ will remain available throughout the European market for years to come, replacing the company's existing certification under the previous Medical Device Directive. Additionally, the MDSAP certification confirms that MSi complies with regulatory frameworks in the United States, Canada, Brazil, and Australia, offering the potential to expand commercial pathways to new markets beyond the US. The MDR...
PR Newswire
21/10/2025

Notice convening an Extraordinary General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 October 2025– Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo Nordisk A/S is called to elect new members to the Board of Directors in accordance with the meeting agenda and proposals included in the enclosed meeting notice.The Extraordinary General Meeting will be held on Friday 14 November 2025 at 14:00 (CET).The Extraordinary General Meeting will be held as a fully electronic general meeting. Accordingly,...
Nasdaq GlobeNewswire
21/10/2025

Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand…

Under the agreement, Gene Tools will provide pre-purified PMO synthesis, while Aji Bio-Pharma will perform purification and quality control. This combination will enable clients to accelerate from early assay-level research to toxicology and GLP studies, creating a smooth path toward clinical development. Under the agreement,Gene Toolswill provide pre-purified PMO synthesis, while Aji Bio-Pharma will perform purification and quality control. This combination will enable clients to...
PR Newswire
21/10/2025

Novo Nordisk announces an Extraordinary General Meeting to be convened to elect…

Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of Novo Nordisk.“Following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors, it has not been possible to reach a common understanding. The Board proposed a renewal focusing on addition of select, new competencies while also maintaining...
Nasdaq GlobeNewswire
21/10/2025

MacuMira and Keeler announce strategic partnership to expand Dry AMD therapy

"Keeler has a proud tradition of advancing eye care with uncompromising quality, craftsmanship and innovation in eyecare," said Andy Harbidge, Managing Director at Keeler. "This partnership marks a transformative moment as we align Keeler's heritage and reach with MacuMira's groundbreaking therapy. Together, we will bring new hope to patients and clinicians worldwide." "Keeler has a proud tradition of advancing eye care with uncompromising quality, craftsmanship and…
PR Newswire
21/10/2025

Change in the Sobi Board of Directors

Sobi®Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough...
PR Newswire
21/10/2025

Biocomposites launches SYNICEM™ spacers in the U.S.

KEELE, England, Oct. 21, 2025 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the launch of its SYNICEM™ hip, knee and shoulder preformed spacers in the United States. KEELE,England , Oct. 21, 2025 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading...
PR Newswire
21/10/2025

UAE-Based Investor Expands Healthcare Bridge Between Dubai and Moldova with GBP…

Over the past decade, BB Hamodialyse has become Moldova's dominant dialysis provider, with over 75% market share and a reputation for affordability and quality of care. Through this acquisition, Handa plans to transform Moldova into a regional centre of excellence for cost-effective dialysis care, while exporting its proven cost effective model to markets across Africa and the Middle East, regions where dialysis access remains limited and demand continues to rise. Over the past decade, BB...
PR Newswire
21/10/2025

Astraveus further strengthens world class leadership team to advance development…

Ken Kotz is a seasoned technical leader with more than 20 years of experience driving innovation across life sciences. His expertise spans microfluidic bioprocessing, optical systems design, product development, and cell therapy process development, including autologous cell therapy manufacturing. Prior to joining Astraveus, Ken served as Director Process Development at bluebird bio, contributing significantly to the commercialization of Lyfgenia™, as well as leading long-term strategy efforts…
PR Newswire
21/10/2025

Acies Bio doubling biomanufacturing capacity with the construction of 30 m³…

3. This infrastructure investment, that plans to be finalized in Q4 2026, represents the next phase in the company’s long-term vision of providing flexible biomanufacturing.At the core of Acies Bio’s strategy lies the principle of flexibility, both across the value chain and across technology sectors. With further integration of additional advanced biomanufacturing capacity with its established R&D and pilot-scale infrastructure, Acies Bio is now adding another important piece of the...
Nasdaq GlobeNewswire
21/10/2025

Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR…

Saint-Genis-Pouilly, France, 21 October 2025– Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer, Philip Beer, will be presenting data on the identification of a CTPS1-dependent synthetic lethality in solid tumours at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, being held from 22-26 October in Boston, MA.The presentation will focus on the use...
Nasdaq GlobeNewswire
21/10/2025

Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G…

CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3GEleva successfully completed the Single Ascending Dose part of the First-in-Human clinical trial evaluating CPV-104 in healthy volunteersThe Safety Review Committee endorsed the study with no safety concerns identified across all four dose cohorts18 patients with C3G will receive now CPV-104 in a Multiple Ascending Dose regimen administered over a four-week period...
Nasdaq GlobeNewswire
21/10/2025

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety…

– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile – STAMFORD, Conn., Oct.21, 2025(GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO ®(nirogacestat), an oral gamma secretase inhibitor for...
Nasdaq GlobeNewswire
21/10/2025

Codis Appoints Steven Facer as Senior VP Sales and Marketing to Support the…

Most recently, Steven served as Senior Vice President of Global Sales and Marketing at Adare Pharma Solutions, where he successfully expanded the company's global market presence and drove significant commercial growth. Prior to this, he held leadership positions in business development, operations, and general management, gaining deep expertise in value pricing, contract negotiations, lean manufacturing, and international business development. Most recently, Steven served as Senior Vice...
PR Newswire
21/10/2025

Embla Medical hf: Interim Report Q3 2025

Interim report Q3 2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted toUSD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched...
PR Newswire
21/10/2025

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the…

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources...
Nasdaq GlobeNewswire
21/10/2025

Neuromod Launches Online Tinnitus Masterclass

Tinnitus Masterclass Increases Tinnitus Care Accessibility Tinnitus Masterclass Increases Tinnitus Care Accessibility Tinnitus, which is commonly known as ringing in the ears, is a complex medical condition that impacts approximately 15% of the global adult population 1. Despite this prevalence, nearly half of all tinnitus patients had to wait more than two months or more for specialist tinnitus care per a 2024 Tinnitus UK report 2. Neuromod's Director of Clinical Affairs and Tinnitus...
PR Newswire
21/10/2025

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS

On September 15, 2025, the Company issued Debentures for an aggregate principal amount of $335,670 convertible into common shares in the capital of the Company ("Shares") at any time, at the option of the holders thereof, at the closing price of the Shares on the Canadian Securities Exchange (the "CSE") on the day notice of conversion is received by the Company, subject to the pricing requirements in the policies of the CSE. The Debentures bear interest at a rate of 10% per…
PR Newswire
21/10/2025

Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical…

Liposarcoma Market Summary Liposarcoma Market Summary Discover the liposarcoma new treatment @New Treatments for Liposarcoma Key Factors Driving the Growth of the Liposarcoma Market Rising Liposarcoma Incidence and Improved Diagnosis The increasing global incidence of liposarcoma, particularly in older populations, is a major factor contributing to market growth. Advancements in diagnostic techniques, such as imaging and molecular profiling, have led to earlier and more...
PR Newswire
20/10/2025

Teva and Prestige Biopharma Enter License Agreement for Tuznue®…

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ®, a biosimilar to Herceptin ®(trastuzumab) Tuznue ®received European Commission (EC) marketing authorization in September 2024Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct.20, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE:...
Nasdaq GlobeNewswire
20/10/2025

Alkermes to Report Third Quarter Financial Results on October 28, 2025

About Alkermes plc About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy...
PR Newswire
20/10/2025

DMS GROUP : ACCELERATION OF GROWTH IN THE 3RD QUARTER 2025

Quarterly revenue of €11.0 million, up +10% Dynamism in the Radiology business (+15% in Q3) Confirmation of the objective of accelerating growth in the 2nd half of 2025 in a less dynamic market context in France and Europe October 20, 2025 – 5:45 pm – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS), a specialist in…
Actusnews Wire
20/10/2025
Altri  Comunicati